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Colorectal cancer is a major health problem. Worldwide,
approximately 500,000 patients per year will die as a result
of colorectal malignancy. The standard therapy is an ade-
quate segmental resection en bloc with the adjacent lymph
nodes. This can be performed by conventional open sur-
gery or laparoscopic resection. Sufficient evidence has
shown equal results in terms of lymph node harvesting,
resection margins, and survival for both techniques. Local
resection for rectal cancer in the early stages has been
shown to be safe, despite the fact that the lymph node
status cannot be established. Transanal endoluminal
microsurgery (TEM) is an effective treatment for early
rectal cancer. However, there has always been concern
about the nodal status and the need for secondary surgery
in case of lymphatic dissemination. Nodal involvement in
T1 tumors has been reported in up to 10%. With (neo-
)adjuvant radiochemotherapy, local resection and tumor
control has been proven to be efficient. Some authors even
consider local resection in early rectal cancer to be a
superior therapy because of the huge impact on quality of
life in case of rectal resection.
Imaging modalities, such as the USPIO MRI technique
and PET scan technology, have improved the resolution to
establish nodal involvement and preoperative staging, but
pathological examination remains the ‘‘gold standard.’’
Colon cancer is diagnosed by endoscopic biopsies or
polyp removal. In case of invading tumors additional
adequate segmental colon resection with en bloc resection
of lymph nodes is common, facilitated by tattooing. Today
local resection for colon cancer is less attractive because of
the restricted possibilities in neoadjuvant treatment
modalities, such as local radiotherapy, and the minor
implications in loss of functionality. Although submucosal
resection of colonic neoplasia is being proposed as a suf-
ficient therapy in selected cases, the uncertainty about the
possible undetected concomitant lymph node metastases
remains a serious drawback of the submucosal resection
technique.
The sentinel node concept has been proven to be valid in
many solid tumors. Since Morton et al. [1] showed the
validity of the concept in melanoma’s and the subsequent
identification of the SLN by lymphatic mapping in breast
cancer by Krag et al. [2] and Giuliano et al. [3], the use of
the SLN in the therapeutic strategy has altered profoundly
the treatment of these cancers.
Similar to melanoma and breast cancer surgery with
sentinel node biopsy, we speculate that local resection with
SLN harvesting in early colon cancer might change the
therapeutic and surgical strategy in colon cancer.
It has been shown that patients who are operated on with
curative intent but who have lymph node metastases benefit
from adjuvant chemotherapy in contrast to those without
metastases.
Stage I and II colorectal cancer implies no lymph node
involvement; however, up to 30% of patients with stage I
or II disease will develop locoregional recurrence or distant
metastases and will eventually die from CRC. Therefore,
standard surgery might not be sufficient in 30% of these
patients. Some of these patients may recur because of
hematogenous metastases, but a significant portion of these
recurrences may occur due to the lack of detecting lymph
node metastases, or aberrant lymphatic drainage beyond
surgical margins.
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The UICC recommend that a minimum of 12 lymph
nodes must be evaluated in all surgically treated colon
cancers [4]. The evaluation of 12 or more lymph nodes has
been demonstrated to improve 5-year survival [5]. Vari-
ability of both surgical technique and pathological harvest
makes it difficult to standardize adequate lymph node
identification.
Furthermore, advanced examination techniques will
increase the likelihood of detecting occult tumor cells
(OTC) or micrometastasis, such as serial sectioning, step
sectioning, immunohistochemistry, polymerase chain
reaction, and reverse transcriptase polymerase chain reac-
tion. The disadvantages of these techniques are that they
are time consuming and expensive.
The detection of the sentinel lymph node could be a
solution for these problems by demonstrating the ability to
increase lymph node harvesting and providing a limited
number of sentinel lymph nodes in which OTC can be
assessed. Despite the progress in recent years in the use and
knowledge of sentinel node procedure in patients with
colorectal cancer, we still face some problems that limit
common use of the sentinel node technique.
Good results of sentinel node harvesting in colorectal
cancers have been shown by large studies. In 2005 Saha
et al. [6] published a multicenter trial that included 500
patients. In SLNM, patients’ success, accuracy, sensitivity,
and negative predictability values were 98%, 96%, 90%,
and 93%, respectively. For future studies it will be neces-
sary to stratify patients according to their T stage. The
sentinel node procedure is likely less reliable in advanced
tumor stages. Another issue is the fact that a learning curve
is probably necessary to obtain good results for SLNM.
Also, the technique for the localization and the definitions
of the sentinel node differ between studies (Table 1). The
following techniques have been used: only blue dye (in
vivo or ex vivo), radioactive dye, and a combination of
radioactive and blue dye or fluorescent dye (indocyanine
green). To our knowledge, a comparative study between all
these techniques has not been performed. Using the same
definition and standardization of the SLNM procedure is
mandatory to validate the sentinel node procedure for
predicting the tumor status of all lymph nodes.
Another problem that we have to overcome is poor
visualization of the tracer. The presence of mesenteric
adipose tissue in patients with colorectal cancer makes is
difficult to see the different kinds of ink. Also blue dye and
indocyanine green can readily diffuse through the sentinel
node and transverse multiple nodes. The use of gamma
tracers for SLNM in patients with colorectal cancer was
first reported by Kitagawa et al. [7]; since then this tech-
nique has been used in different studies in combination
with ink or as a tracer on itself. Even though the overall
results do not show an additional value of the use of
radioactive tracers, we think that the combination tech-
nique is preferable. Saha et al. [8] published data that
indicate that a combination of isosulfan blue and a radio-
active tracer may improve the identification, accuracy rate,
and number of SLNs. In 2006 (our group) Terwisscha Van
Scheltinga et al. [9] showed that in three patients (17%) the
positive SLN was detected by scintigraphy only and not
with patent blue. Using a radioactive tracer alone presents
the problem of signal interference of the injection site and a
SLN situating near the tumor.
New horizons
In 2003 Bilchik et al. [10] reported the feasibility of lap-
aroscopic intraoperative lymphatic mapping with blue dye
in 30 patients. The sentinel node analysis was shown to be
efficient with a 93% accuracy rate. In 29% of patients
unexpected lymph drainage altered the initial surgical
procedure. Recently the group of Marescaux published a
study of the sentinel node biopsy by Natural Orifice
Transluminal Endoscopic Surgery (NOTES) technique
[11]. They localized and harvested successfully the sentinel
node in six pigs by using submucosal injection of methy-
lene blue. In humans with a fatty mesentery, methylene
blue, as said, might not be the preferred dye because of
poor tissue contrast.
In 2006 Nagata et al. [12] demonstrated successful
laparoscopic sentinel node mapping using infrared ray
laparoscopy (IRL) with indocyanine green staining. In 48
patients, IRL was shown to be five timers superior in
localizing the SLN compared with conventional laparos-
copy. As with methylene blue, indocyanine green also has
disadvantages; it has poor penetration in fatty tissues (2–
3 mm) and therefore is difficult to detect. Also, both dyes
are small particles (\5 nm) and diffuse easily through
lymphatic channels and (sentinel) lymph nodes.
The use of quantum dots (QD, nanocrystals with a metal
shell and solubilizing organic coating), as published by
Frangioni et al. [13], can enhance visibility because QDs
Table 1 Definitions of the sentinel lymph node used in the literature
A sentinel node is:
Lymph node upon which the primary tumor directly drains
Lymph node that is the nearest to the primary tumor
Radioactive lymph node
Most radioactive lymph node
First lymph node found by lymphoscintigraphy
Lymph node that has a certain factor higher radioactivity than the
other lymph nodes or that of the local normal tissue
Lymph node that is blue of color
Lymph node that is visualized by infrared irradiation
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are highly fluorescent, nonradioactive, and visible deep
within tissue. Because of their size, QDs remain trapped in
the lymph nodes. The unknown toxicity of the metals are
restricting human use at present, although the doses used
are far below (acute) toxic levels.
The use of a fluorescent dye conjugated with monoclo-
nal antibodies, as published by Gutowski et al. [14], could
be significant in the future.
If we can enhance the fluorescent properties of the dye
and bind them at malignant cells, it may be easier to detect
the SLN. Also the intraoperative lymphatic mapping can
reveal an aberrant lymphatic drainage as high as 30% [10].
Conclusions
Screening programs and increasing awareness of the
symptoms of colorectal cancer will lead to increased
numbers of detection of early-stage colon neoplasia with-
out nodal involvement. The present standard surgical
treatment may overtreat substantial numbers of patients
who can benefit from local resection only and undertreat
those who have lymphatic micrometastases. Despite the
present difficulties in sentinel node lymphatic mapping in
patients with colon cancer, minimal invasive detection and
harvesting of the sentinel node will be important in future
treatment of colonic neoplasia. The technique that is the
most reliable for sentinel node detection has not yet been
validated; however, the fluorescent technique seems very
promising. Development of near-infrared devices for
excitation and visualization of the fluorescent dyes will be
necessary to optimize the potential of this technique.
Early colon cancers may be treated by local resection
therapy only with a minimal invasive surgical sentinel node
procedure. Similar to breast cancer surgery, these tech-
niques may profoundly alter the way that we treat colon
cancer, but only if the sentinel node can be detected and
harvested in an accurate, safe, and reliable manner.
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